Elsevier

Gynecologic Oncology

Volume 79, Issue 2, November 2000, Pages 147-153
Gynecologic Oncology

Regular Article
A Phase III Trial of Ifosfamide with or without Cisplatin in Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study

https://doi.org/10.1006/gyno.2000.6001Get rights and content

Abstract

Objective. The aims of this study were to substantiate the previously reported activity of ifosfamide in patients with advanced, persistent, or recurrent carcinosarcoma (mixed mesodermal sarcoma) of the uterus, and to determine whether the addition of cisplatin results in an improved response or survival. Secondarily, we sought to determine the toxicity of ifosfamide–cisplatin in this patient population.

Methods. Patients were randomized to receive ifosfamide (1.5 g/m2/day) times 5 days every 3 weeks for eight courses with mesna uroprotection, with or without cisplatin (20 mg/m2/day) times 5 days. No patient had received previous chemotherapy.

Results. Of 224 patients entered on this study, 30 were ineligible for a variety of reasons, leaving 194 evaluable patients. Early in the study, the dose of the combination regimen was reduced by 20% (1 day) because of toxicity. The investigational arms were balanced for age, grade, and Gynecologic Oncology Group performance status. Percentages of adverse effects reported in 191 patients receiving chemotherapy included (ifosfamide/cisplatin–ifosfamide) grade 3 or 4 granulocytopenia (36/60), grade 3 or 4 anemia (8/17), grade 3 or 4 central nervous system toxicity (19/14), and grade 3 or 4 peripheral neuropathy (1/12). Treatment may have contributed to the deaths of 6 patients treated with full doses of ifosfamide and cisplatin for 5 days. The proportion of patients responding to ifosfamide alone versus ifosfamide–cisplatin therapy was (0.36 versus 0.54) overall, 0.47 versus 0.61 for pelvic, 0.21 versus 0.54 for lung, and 0.33 versus 0.40 for “other” metastatic sites of measurable disease. The relative odds ratio of response adjusted for measurable sites of disease was 1.82 (P = 0.03, one-tailed test; 95% lower confidence limit, 1.06). Progression-free survival (PFS) and survival data suggest that the combination offers a slight prolongation of PFS (relative risk, 0.73; 95% upper confidence limit, 0.94; P = 0.02, one-tailed test), but no significant survival benefit (relative risk, 0.80, 95% upper confidence limit, 1.03; P = 0.071, one-tailed test).

Conclusion. The addition of cisplatin to ifosfamide appears to offer a small improvement in progression-free survival over ifosfamide alone in the management of advanced carcinosarcoma of the uterus; the added toxicity may not justify the use of this combination.

References (30)

  • LH Einhorn

    VP-16 plus ifosfamide plus cisplatin as salvage therapy in refractory testicular cancer

    Cancer Chemother Pharmacol

    (1986)
  • EL Kaplan et al.

    Nonparametric estimation from incomplete observations

    J Am Stat Assoc

    (1958)
  • N Mantel

    Evaluation of survival data and two new rank order statistics arising in its consideration

    Cancer Chemother Rep

    (1966)
  • DR Cox

    Regression models and life-tables

    J R Stat Soc B

    (1972)
  • Cited by (224)

    • Adenocarcinoma of the uterine corpus and sarcomas of the uterus

      2023, DiSaia and Creasman Clinical Gynecologic Oncology
    • Uterine carcinosarcoma

      2023, Diagnosis and Treatment of Rare Gynecologic Cancers
    • Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26)

      2022, Gynecologic Oncology
      Citation Excerpt :

      The disease stage (stage I-II vs III-IV), age (≥70 years) and the presence of macroscopic residual disease are considered as poor prognostic factors, whereas the primary location, with a somewhat worse prognosis for women with OC, and the histological type may be predictive factors for the efficacy of chemotherapy or radiotherapy [5–9]. For both OC and US, the backbone treatment remains complete surgical cytoreduction followed, even in early stage, by platinum-based chemotherapy, usually with the combination of carboplatin-paclitaxel or with cisplatin and ifosfamide [8,10–15]. Recently, a phase III randomized trial in patients with carcinosarcoma of the uterus or ovary has reported that the combination of paclitaxel and carboplatin is not inferior to the active regimen of paclitaxel and ifosfamide and thus should be standard treatment for those patients [16].

    • Adjuvant therapy and prognosis in uterine carcinosarcoma

      2021, Journal of the Formosan Medical Association
    • Uterine carcinosarcoma: An overview

      2021, Critical Reviews in Oncology/Hematology
    View all citing articles on Scopus

    Please address reprint requests to GOG Administrative Office, Suite 1945, 1234 Market Street, Philadelphia, PA 19107.

    2

    Present address: Department of Gynecologic Oncology, St. Vincent Hospitals and Health Services, 2001 East 86th Street, Indianapolis, IN 46260.

    View full text